uTRACE-arkiv - Page 2 of 3 - BioStock

Curasight secures deal with Curium

Curasight secures global licence agreement for uTRACE in prostate cancer

11 May, 2023

Curasight comments the Curium deal

Curasight on the agreement with Curium

10 May, 2023

Curasight Q3 2022

Curasight eagerly awaiting phase II-results in brain cancer

1 December, 2022

Curasight starts preclinical studies with uTREAT

Curasight takes the next step in the two new indications

24 October, 2022

Curasight has a strong momentum

Strong momentum for Curasight in first half of 2022

2 September, 2022

Curasight has completed recruitment

Curasight ready to move forward in brain cancer

5 July, 2022

Strong first quarter for Curasight

Curasight starts 2022 off strong

3 June, 2022

Curasight targets neuroendokrina tumörer

Curasight targets neuroendocrine tumours

27 April, 2022

Positive results for Curasight in neuroendocrine cancer

Positive phase II results for Curasight in neuroendocrine cancer

17 February, 2022

BioStock looks at Curasight´s potential in brain cancer

BioStock takes a closer look at Curasight´s potential in brain cancer

1 February, 2022

123 Page 2 of 3